Get the Stockscreener App
106.38
0.82%
0.87
After Hours:
106.57
0.19
+0.18%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $106.38, with a volume of 7.77M.
It is up +0.82% in the last 24 hours and down -0.65% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$105.51
Open:
$105.95
24h Volume:
7.77M
Relative Volume:
0.91
Market Cap:
$130.75B
Revenue:
$28.75B
Net Income/Loss:
$480.00M
P/E Ratio:
287.51
EPS:
0.37
Net Cash Flow:
$10.31B
1W Performance:
+1.43%
1M Performance:
-0.65%
6M Performance:
+21.95%
1Y Performance:
+58.71%
1-Day Range:
$99.32
$106.64
1-Week Range:
$99.32
$106.64
52-Week Range:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
106.38 | 130.75B | 28.75B | 480.00M | 10.31B | 0.37 |
|
LLY
Lilly Eli Co
|
829.42 | 744.96B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
155.38 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
177.05 | 303.70B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
61.30 | 279.13B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.13 | 216.43B | 51.72B | 11.94B | 13.81B | 5.88 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
P/E Ratio Insights for Gilead Sciences - Benzinga
As Trump administration battles DEI, Gilead highlights its efforts - The Business Journals
Gilead Sciences's Options Frenzy: What You Need to Know - Benzinga
Biomedical HIV Prevention Summit in Atlanta Is the Focus To Drive Meaningful Action With Gilead Sciences - CSRwire
Gilead Sciences (GILD) Earnings Report Preview: Key Insights for Investors - GuruFocus
Gilead Sciences Q1 2025 Earnings Preview (GILD:NASDAQ) - Seeking Alpha
Exploring Gilead Sciences's Earnings Expectations - Nasdaq
In Europe, Gilead flags CAR T access challenges - The Pharma Letter
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi - Yahoo Finance
Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Promising Commercial Potential for Gilead’s Trodelvy Following Successful ASCENT-04 Trial - TipRanks
Trodelvy plus Keytruda effective for aggressive breast cancer type: Gilead Sciences - Medical Dialogues
GILEAD SCIENCES Earnings Preview: Recent $GILD Insider Trading, Hedge Fund Activity, and More - Nasdaq
Gilead reports topline data from Phase III trial of Trodelvy combo therapy - Clinical Trials Arena
Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy - Baystreet.ca
Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds? - Insider Monkey
Press Release Distribution & PR Platform - ACCESS Newswire
Cantor Fitzgerald maintains Overweight on Gilead with $125 target By Investing.com - Investing.com India
Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer - BioSpace
Cantor Fitzgerald raises Gilead stock target to $125, cites HIV drug - Investing.com
Gilead Sciences (GILD) Upgraded by Cantor Fitzgerald with Positive Outlook | GILD Stock News - GuruFocus
Gilead Sciences to propel healthcare innovation and cell therapy advancement in Abu Dhabi - BioSpectrum Asia
Lobbying Update: $1,662,000 of GILEAD SCIENCES INC lobbying was just disclosed - Nasdaq
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type - Reuters
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News
11 Cheap NASDAQ Stocks to Buy According to Hedge Funds - Insider Monkey
Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC - insights.citeline.com
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer - Benzinga
Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal - FirstWord Pharma
Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC - Yahoo Finance
Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer - Fierce Pharma
Gilead Sciences (GILD) Surprises with Positive ASCENT-04 Results, Analyst Optimistic | GILD Stock News - GuruFocus
Gilead Sciences (GILD) Reports Positive Phase 3 Results for Breast Cancer Treatment | GILD Stock News - GuruFocus
Gilead's (GILD) Trodelvy Shows Promise in Breast Cancer Study - GuruFocus
Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study - marketscreener.com
Gilead Trodelvy + Merck Keytruda combo excels in first-line breast cancer - Seeking Alpha
Gilead Sciences Reports Positive Data From Phase 3 ASCENT-04/KEYNOTE-D19 Study - Nasdaq
Gilead says its therapy delayed growth of tumors in aggressive form of breast cancer - statnews.com
Gilead Sciences (GILD); Trodelvy Plus Keytruda Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients With nTNBC - StreetInsider
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer - Business Wire
Cancer Immunotherapy Market Is Booming So Rapidly 2025-2032 - openPR.com
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences: Strong Financial Outlook and Strategic Positioning Justify Buy Rating - TipRanks
4,126,119 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Bought by Gilead Sciences Inc. - MarketBeat
Lobbying Update: $60,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings - MSN
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - MSN
BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115 - marketscreener.com
Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating - marketscreener.com
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
2.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):